NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting

NCT05487703

CompletedN/A

Sponsor: Pfizer

Conditions: Arthritis, Rheumatoid

Countries: Morocco

This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Enrolled in the CorEvitas RA Registry and initiated tofacitinib on or after November 2012.
* Initiate tofacitinib (defined as first ever use of tofacitinib) at Registry enrollment visit or at a Registry follow-up visit after November 2012
* Have prior use of rituximab
* Have CDAI measured at baseline and appropriate follow-up visit.

Exclusion Criteria:

* There are no exclusion criteria for this study

Locations (1)

Casablanca, Morocco